EnsiliTech® Reaches Prestigious Finals of OBN Awards and Named Among Top 50 Startups in Santander X Awards
Bristol, 8th September 2025 – EnsiliTech, a pioneering biotechnology company dedicated to revolutionising the global transport and storage of medicines through its groundbreaking Ensilication® technology, is proud to announce two major milestones of recognition in its journey:
Finalist in the Best Emerging Biotech category at the OBN Awards 2025, one of only three companies selected for this highly prestigious honour.
Shortlisted to the Top 50 in the Startup category of The Santander X UK Awards 2025, from an original pool of 391 entrants.
The OBN Awards celebrate excellence in the UK’s life sciences sector and are widely regarded as a mark of industry leadership. Being named one of just three finalists for Best Emerging Biotech underlines EnsiliTech’s innovative approach to transforming cold-chain logistics and its potential to make a global healthcare impact.
The OBN Awards, now in their 17th year, celebrate innovation and achievement across the UK life sciences sector, recognising companies driving progress in biotechnology, medtech, and investment. Being named a finalist for Best Emerging Biotech highlights EnsiliTech’s innovative approach to transforming cold-chain logistics and its potential to make a global healthcare impact.
The Santander X Awards recognise high-potential startups across industries, championing bold ideas with the power to scale internationally. Reaching the Top 50 out of nearly 400 startups highlights EnsiliTech’s momentum and the strength of its vision for transforming the accessibility and sustainability of biologics worldwide.
“To be recognised by both the OBN Awards and the Santander X Awards at this stage is a tremendous honour,” said Asel Sartbaeva, CEO and co-founder of EnsiliTech. “These acknowledgements validate the dedication of our team and the real-world impact of our mission — to make vital treatments more stable, more accessible, and more sustainable.”
The winners of the OBN Awards will be announced on 26th November 2025 at an awards ceremony at the Royal Lancaster Hotel in London, with further final rounds of the Santander X Awards also concluding in November.
About EnsiliTech
Ensilicated Technologies Ltd is a pioneering biotechnology company dedicated to enhancing the stability and accessibility of biopharmaceuticals through its proprietary Ensilication technology. EnsiliTech is a Bristol-based startup, which spun out from the University of Bath in 2022. Our mission is to democratise access to therapeutics and biologicals by making them room-temperature stable; improving logistics whilst reducing overall environmental impact.
In August 2025, EnsiliTech raised a second oversubscribed funding round, achieving £4.5M in seed funding. This consisted of investment from Eos Advisory, Calculus Capital, Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol (AIB), HERmesa, Penn Park Capital, chANGELS, and other individual angel investors.
For more information about EnsiliTech please visit www.ensilitech.com, connect on LinkedIn or contact us on hello@ensilitech.com.